(Bloomberg) -- Shire Plc's only patent on its colitis drug Lialda was upheld after a U.S. patent agency review requested by hedge fund manager Kyle Bass.
The Patent Trial and Appeal Board conducted its yearlong review to determine if the patent, owned by Cosmo Pharmaceuticals NV and licensed to Shire, covered a new invention. Bass and his Coalition for Affordable Drugs had petitioned to have the patent deemed invalid.
To contact the reporter on this story: Susan Decker in Washington at sdecker1@bloomberg.net.
To contact the editor responsible for this story: Elizabeth Wasserman at ewasserman2@bloomberg.net.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
